Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.

The journal of pathology. Clinical research - 1 Mar 2024

Forster-Sack Miriam, Zoche Martin, Pestalozzi Bernhard, Witzel Isabell, Schwarz Esther Irene, Herzig Joel Julien, Fansa Hisham, Tausch Christoph, Ross Jeff, Moch Holger, Varga Zsuzsanna

Abstract excerpt

Most invasive lobular breast carcinomas (ILBCs) are luminal-type carcinomas with an HER2-negative phenotype (ERBB2 or HER2 un-amplified) and CDH1 mutations. Rare variants include ERBB2-amplified subtypes associated with an unfavorable prognosis and less response to anti-HER2 targeted therapies. We analyzed the clinicopathological and molecular features of ERBB2-amplified ILBC and compared these characteristics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Carcinoma, Lobular

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinases

Share to Erb-b2 Receptor Tyrosine Kinases

Share to SOX10 gene

Share to In Situ Hybridization, Fluorescence

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 38335502
DOI: 10.1002/2056-4538.12362
PMCID: PMC10800294

Genes

ERBB2
CDK12
CDH1
SOX10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.PMID 38335502Read ↗

<i>ERBB2</i> / <i>HOXB13</i> co-amplification with interstitial deletion of <i>BRCA1</i> defines a unique subset of breast cancersSemantic proximity Read ↗

ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.Semantic proximity Read ↗

Genomic Characterization of Primary Invasive Lobular Breast Cancer.Semantic proximity Read ↗

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.Semantic proximity Read ↗

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.Semantic proximity Read ↗

DNA amplifications in breast cancer: genotypic-phenotypic correlations.Semantic proximity Read ↗

Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.Semantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.